--- title: 5 Areas in Adverse Event Reporting to Consider description: Read how adverse event reporting in Europe has begun to exceed traditional activities to prioritize the safety of patients. image: https://blog.ubc.com/hubfs/5%20AE%20Consider%20Featured%20Image.png --- [![UBC](https://blog.ubc.com/hs-fs/hubfs/raw_assets/public/UBC_December2021/images/logo-white.png?width=175&name=logo-white.png "UBC")](https://ubc.com/) - [Home](https://ubc.com/) - Services - [Full-Service Clinical Development](https://ubc.com/global-services/) - [Clinical Trial Management & Late Stage Research](https://ubc.com/global-services/trials-and-research/) - [Decentralized Studies & Virtual Engagement](https://ubc.com/global-services/decentralized/) - [Patient & Physician Services](https://ubc.com/global-services/pps/) - [Pharmacovigilance](https://ubc.com/global-services/pharmacovigilance/) - [Risk Management Plans](https://ubc.com/global-services/risk-management/) - [Risk Evaluation and Mitigation Strategies (REMS)](https://ubc.com/global-services/rems/) - [Registries & Observational Studies](https://ubc.com/global-services/registries/) - [Safety & Epidemiology Consulting](https://ubc.com/global-services/epidemiology/) - [Become a Clinical Trial Investigator](https://ubc.com/global-services/become-an-investigator/) - [Patient Support Services](https://ubc.com/patient-support/) - [Access Services](https://ubc.com/patient-support/access-services/) - [Clinical Education](https://ubc.com/patient-support/clinical-education/) - [Connected Health](https://ubc.com/patient-support/connected-health/) - [In-Home Care Coordination](https://ubc.com/patient-support/care-coordination/) - [In-Workflow Services](https://ubc.com/patient-support/in-workflow-services/) - [Outcomes and Value](https://ubc.com/patient-support/outcomes-and-value/) - [Patient Engagement](https://ubc.com/patient-support/patient-engagement/) - [Real World Evidence](https://ubc.com/real-world-evidence/) - [RWE Consulting Practice](https://ubc.com/real-world-evidence/rwe-consulting/) - [Real World Data](https://ubc.com/real-world-evidence/real-world-data/) - [Mosaic Technology Platform](https://ubc.com/real-world-evidence/mosaic-technology-platform/) - [Automated Analytics Software](https://ubc.com/real-world-evidence/analytics-software/) - [Product Lifecycle Solutions](https://ubc.com/product-lifecycle/) - [Cell & Gene Therapy](https://ubc.com/product-lifecycle/cell-gene/) - [COVID-19](https://ubc.com/product-lifecycle/patient-care/) - [Oncology](https://ubc.com/product-lifecycle/oncology/) - [Nursing](https://ubc.com/product-lifecycle/nursing/) - [Rare Disease](https://ubc.com/product-lifecycle/rare-disease/) - [Technology](https://ubc.com/technology/) - [Automated Analytics Software](https://ubc.com/technology/automated-analytics-software/) - [Connected Health](https://ubc.com/technology/connected-health/) - [Decentralized Studies & Virtual Engagement](https://ubc.com/technology/decentralized-studies-virtual-engagement/) - [Mosaic Technology Platform](https://ubc.com/technology/mosaic-technology-platform/) - [Patient Engagement](https://ubc.com/technology/engage/) - [Think Tank](https://blog.ubc.com/blog) - About - [About UBC](https://ubc.com/about/) - [Awards](https://ubc.com/about/awards/) - [Leadership Team](https://ubc.com/about/leadership/) - [Press Releases](https://ubc.com/about/press/) - [Careers](https://ubc.com/careers/) [SUBMIT RFI/RFP](https://ubc.com/contact/) Menu [![UBC](https://blog.ubc.com/hs-fs/hubfs/raw_assets/public/UBC_December2021/images/logo-white.png?width=175&name=logo-white.png "UBC")](https://ubc.com/) - [Home](https://ubc.com/) - Services - [Full-Service Clinical Development](https://ubc.com/global-services/) - [Clinical Trial Management & Late Stage Research](https://ubc.com/global-services/trials-and-research/) - [Decentralized Studies & Virtual Engagement](https://ubc.com/global-services/decentralized/) - [Patient & Physician Services](https://ubc.com/global-services/pps/) - [Pharmacovigilance](https://ubc.com/global-services/pharmacovigilance/) - [Risk Management Plans](https://ubc.com/global-services/risk-management/) - [Risk Evaluation and Mitigation Strategies (REMS)](https://ubc.com/global-services/rems/) - [Registries & Observational Studies](https://ubc.com/global-services/registries/) - [Safety & Epidemiology Consulting](https://ubc.com/global-services/epidemiology/) - [Become a Clinical Trial Investigator](https://ubc.com/global-services/become-an-investigator/) - [Patient Support Services](https://ubc.com/patient-support/) - [Access Services](https://ubc.com/patient-support/access-services/) - [Clinical Education](https://ubc.com/patient-support/clinical-education/) - [Connected Health](https://ubc.com/patient-support/connected-health/) - [In-Home Care Coordination](https://ubc.com/patient-support/care-coordination/) - [In-Workflow Services](https://ubc.com/patient-support/in-workflow-services/) - [Outcomes and Value](https://ubc.com/patient-support/outcomes-and-value/) - [Patient Engagement](https://ubc.com/patient-support/patient-engagement/) - [Real World Evidence](https://ubc.com/real-world-evidence/) - [RWE Consulting Practice](https://ubc.com/real-world-evidence/rwe-consulting/) - [Real World Data](https://ubc.com/real-world-evidence/real-world-data/) - [Mosaic Technology Platform](https://ubc.com/real-world-evidence/mosaic-technology-platform/) - [Automated Analytics Software](https://ubc.com/real-world-evidence/analytics-software/) - [Product Lifecycle Solutions](https://ubc.com/product-lifecycle/) - [Cell & Gene Therapy](https://ubc.com/product-lifecycle/cell-gene/) - [COVID-19](https://ubc.com/product-lifecycle/patient-care/) - [Oncology](https://ubc.com/product-lifecycle/oncology/) - [Nursing](https://ubc.com/product-lifecycle/nursing/) - [Rare Disease](https://ubc.com/product-lifecycle/rare-disease/) - [Technology](https://ubc.com/technology/) - [Automated Analytics Software](https://ubc.com/technology/automated-analytics-software/) - [Connected Health](https://ubc.com/technology/connected-health/) - [Decentralized Studies & Virtual Engagement](https://ubc.com/technology/decentralized-studies-virtual-engagement/) - [Mosaic Technology Platform](https://ubc.com/technology/mosaic-technology-platform/) - [Patient Engagement](https://ubc.com/technology/engage/) - [Think Tank](https://blog.ubc.com/blog) - About - [About UBC](https://ubc.com/about/) - [Awards](https://ubc.com/about/awards/) - [Leadership Team](https://ubc.com/about/leadership/) - [Press Releases](https://ubc.com/about/press/) - [Careers](https://ubc.com/careers/) - [Submit RFI/RFP](https://ubc.com/contact/) Anesthesiology 1. [Home](https://ubc.com/) 2. [Blog](https://blog.ubc.com/blog) 3. 5 Areas in Adverse Event Reporting to Consider # 5 Areas in Adverse Event Reporting to Consider *Thursday, March 14, 2019* Traditionally, sources of adverse event reporting included the clinical trial investigator sites, post-marketing medical information call centers, and local QPs in Europe. However, currently, potential adverse event reporting is occurring outside of these traditional modalities. Below, I have provided insight into ensuring AEs are being monitored and captured properly, regardless of their source. Here are a few points to keep in mind:   - **Non-Traditional AE Reporting** More than ever, AEs are being reported from non-traditional sources including product websites, social media, and sites of care.  You must have documented safety reporting plans and training in place. - **Patient Interaction Programs – Do they meet the necessary requirements?** Manufacturers are providing additional patient support options for their products. Common Patient Interaction Programs include: specialty pharmacies, patient assistance programs (PAPs), pharmacy benefit managers (PBM), REMS KAB and other surveys, reimbursement Hubs, medication/patient adherence services, and market research programs. The Pharmacovigilance team needs to be kept abreast of the implementation of such programs and a system for reporting needs to be determined. Both the FDA and the MHRA are looking closely at the above AE reporting processes during inspections.  A review of sample audits found multiple instances of a citation for lack of training and documentation related to AEs for patient interaction settings. - **Training documentation** Patient Interaction Programs staff may be aware of AE reporting, but many do not understand all required reporting. It is your responsibility as the Marketing Authorization Holder (MAH) to ensure** documented** training has taken place for all patient interaction programs and staff. - **Ongoing monitoring** Monitoring is key. You should be aware of programs being conducted, ensure documented SOPs are in place for AE capture and triage, and ensure vendor contracts and master service agreements have a safety reporting provision. - **Audits mitigate risk** Audits of these programs and sites can and should be used to help mitigate the risk of unreported AEs and to demonstrate vendor oversight. --- As experts in Pharmacovigilance, UBC understands Product safety. For more information on our [Pharmacovigilance services](https://ubc.com/global-services/pharmacovigilance/) or to speak with one of our experts, please click [here, ](https://ubc.com/contact/)and a member of my team would be happy to assist in ensuring the proper oversight is in place for all of your adverse event reporting. ## Related Articles ## [Decentralized Research Playbook](https://blog.ubc.com/blog/decentralized-research-playbook) The UBC Decentralized Research Playbook is intended to help inform and offer a practical assessment method to... [Read More](https://blog.ubc.com/blog/decentralized-research-playbook) ## [Efficient Technological Advancements for Your REMS Program](https://blog.ubc.com/blog/tech-advancements-for-rems-program) After 15 years, there is still continuous improvement that can be implemented for Risk Evaluation and... [Read More](https://blog.ubc.com/blog/tech-advancements-for-rems-program) ## [Is Your Organization Pharmacovigilance Ready?](https://blog.ubc.com/blog/are-you-pv-ready) The right strategy to continually evaluate product safety in your clinical trials, through regulatory review... [Read More](https://blog.ubc.com/blog/are-you-pv-ready) ![Footer Logo](https://blog.ubc.com/hs-fs/hubfs/raw_assets/public/UBC_December2021/images/logo-blue.jpg?width=113&name=logo-blue.jpg "Footer Logo") #### Quick Links - Subscribe to Think Tank - [Contact UBC](https://ubc.com/contact) - [Privacy](https://ubc.com/privacy-policy) - [Terms of Use](https://ubc.com/terms-of-use) - [Sitemap](https://ubc.com/sitemap) #### RECENT ARTICLES - [Planning for Diversity in Clinical Trials](https://blog.ubc.com/blog/planning-for-diversity-in-clinical-trials) - [Practical Considerations for Evidence Generation](https://blog.ubc.com/blog/practical-considerations-rwe) - [Supporting Patients and Families Through Case Management](https://blog.ubc.com/blog/supporting-patients-and-families-through-case-management) Copyright © 2017-2026 United BioSource LLC, all rights reserved. UBC®, CLÆRITY®, SæfetyWorks®, ExpressConnect® and UBC Pathways® are trademarks of United BioSource LLC. ![close button](https://blog.ubc.com/hubfs/close.png) ### Subscribe to Think Tank #### Look for more industry-related insight coming soon! Thank you for your interest in UBC’s thought leadership!